๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Precursor B-Cell Acute Lymphoblastic Leukemia

CAV Regimen for R/R Ph- B-ALL NCT05657652NA1 site๐Ÿ“ Suzhou The First Affiliated Hospital of Soochow University ยท Tests: cladribine, cytarabine,venetoclax Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies NCT06508775NA7 sites๐Ÿ“ Berlin๐Ÿ“ Cologne๐Ÿ“ Erlangen Miltenyi Biomedicine GmbH ยท Tests: MB-CART19.1, MB-CART20.1, MB-CART2019.1 Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT07572136Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: TSLPR-CART, Cyclophosphamide, Fludarabine Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL NCT06481228NA1 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: CAR-T cells, Venetoclax, Olverembatinib Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia NCT07328503Phase 21 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia NCT07400029Phase 29 sites๐Ÿ“ Duarte๐Ÿ“ Stanford๐Ÿ“ Basking Ridge Memorial Sloan Kettering Cancer Center ยท Tests: Obecabtagene Autoleucel Newly-diagnosed Pediatric Ph-positive B-ALL Protocol NCT07152041Phase 324 sites๐Ÿ“ Hefei๐Ÿ“ Chongqing๐Ÿ“ Fuzhou Institute of Hematology & Blood Diseases Hospital, China ยท Tests: olverembatinib Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies NCT05887167Phase 11 site๐Ÿ“ Los Angeles Joshua Sasine, MD, PhD ยท Tests: autologous hematopoietic stem cells added to planned CAR T The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen NCT01890486n/a1 site๐Ÿ“ Winston-Salem Wake Forest University Health Sciences Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies NCT06037018Phase 11 site๐Ÿ“ Tianjin CytoCares Inc ยท Tests: CC312 Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia NCT07109219Phase 1, Phase 227 sites๐Ÿ“ Duarte๐Ÿ“ Jacksonville๐Ÿ“ Chicago AstraZeneca ยท Tests: AZD4512 monotherapy "Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL NCT06919393n/a3 sites๐Ÿ“ Meldola๐Ÿ“ Ravenna๐Ÿ“ Rimini Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRโ€ฆ ยท Tests: "Triple negative" adul B-cell ALL International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) NCT07476729Phase 321 sites๐Ÿ“ Vienna๐Ÿ“ Ghent๐Ÿ“ Prague Charite University, Berlin, Germany ยท Tests: Inotuzumab ozogamicin (INO), Blinatumomab CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRฮฑฮฒ/CD19 Depleted HSCT NCT03810196NA1 site๐Ÿ“ Philadelphia Children's Hospital of Philadelphia ยท Tests: CliniMACS Cell Processing System for TCRฮฑฮฒ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback CD-19 CAR-T Cell for Pediatric ALL or Lymphoma NCT06866873NA1 site๐Ÿ“ Hong Kong Hong Kong Children's Hospital ยท Tests: CAR-T MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia NCT07371403NA1 site๐Ÿ“ Amman King Hussein Cancer Center ยท Tests: MB-CART19.1 MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol NCT06764238Phase 2, Phase 327 sites๐Ÿ“ Hefei๐Ÿ“ Hefei๐Ÿ“ Fuzhou Institute of Hematology & Blood Diseases Hospital, China ยท Tests: Blinatumomab (Group A), Venetoclax (nonRand Group), Blinatumomab (Group B) Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies NCT06227026Phase 11 site๐Ÿ“ Salt Lake City University of Utah ยท Tests: Anti-CD19 CAR-T cells Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL NCT03937544Phase 2, Phase 31 site๐Ÿ“ Bandar Tun Razak National University of Malaysia ยท Tests: CD19 CAR-T CELLS, Cyclophosphamide, Fludarabine Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL NCT05082519Phase 216 sites๐Ÿ“ Los Angeles๐Ÿ“ Orange๐Ÿ“ San Francisco Etan Orgel ยท Tests: IDEAL2 Intervention Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Senl_B19 autologous CAR-T (S1904) treatment Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse NCT06649253NA3 sites๐Ÿ“ Angers๐Ÿ“ Brest๐Ÿ“ Rennes Rennes University Hospital ยท Tests: Sampling bone tissue and blood CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies NCT05442515Phase 1, Phase 21 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 NCT05535855Phase 11 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19 Directed CAR T Cell TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT06481735Phase 1, Phase 26 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Fludarabine, Cyclophosphamide A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation NCT06859424Phase 213 sites๐Ÿ“ Birmingham๐Ÿ“ Duarte๐Ÿ“ Palo Alto Center for International Blood and Marrow Transplant Researโ€ฆ ยท Tests: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph... NCT05621291NA8 sites๐Ÿ“ Los Angeles๐Ÿ“ Washington D.C.๐Ÿ“ Atlanta National Cancer Institute (NCI) ยท Tests: NGS testing
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy